Don’t Forget About Brexanolone’s Little Sister: Zuranolone
While we have been talking about using brexanolone, marketed by Sage Therapeutics as Zulresso, for the treatment of postpartum depression, an oral version of this novel antidepressant – SAGE 217 or zuranolone – has been finishing up its Phase 3 trials. Like brexanolone, SAGE-217 is a neurosteroid, an analogue of allopregnanolone which is a positive… Read More »